Stock Events

Omeros 

$4.97
0
+$0+0% Friday 16:50

Statistics

Day High
5.02
Day Low
4.96
52W High
7.78
52W Low
0.99
Volume
7,368
Avg. Volume
2,368
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

7MayExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q1 2024
-0.65
0.25
1.15
2.05
Expected EPS
-0.58
Actual EPS
-0.15

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0KBU.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap118.74B
Regeneron Pharmaceuticals competes in the biotech space, focusing on treatments that could directly compete with Omeros' drug portfolio, especially in areas like immunology and inflammation.
Vertex Pharmaceuticals
VRTX
Mkt Cap126.12B
Vertex Pharmaceuticals operates in similar therapeutic areas as Omeros, including rare diseases, making them direct competitors in the biotech market.
Biogen
BIIB
Mkt Cap33.5B
Biogen competes with Omeros in the biotechnology and pharmaceuticals sector, particularly in areas related to neurological conditions and rare diseases.
AMGEN
AMGN
Mkt Cap177.47B
Amgen competes across several of the same biotech and pharmaceutical areas as Omeros, including treatments for inflammatory diseases.
Gilead Sciences
GILD
Mkt Cap87.16B
Gilead Sciences competes with Omeros in the development of innovative therapies, particularly in areas like immunology.
Abbvie
ABBV
Mkt Cap300.69B
AbbVie competes in similar therapeutic areas as Omeros, including immunology and neurological diseases, with a broad portfolio of biopharmaceuticals.
Novartis
NVS
Mkt Cap244.62B
Novartis competes with Omeros in multiple areas, including the development of treatments for rare diseases and chronic conditions.
Pfizer
PFE
Mkt Cap163.88B
Pfizer competes with Omeros through its extensive range of pharmaceutical products, including those in the immunology and inflammation sectors.
Johnson & Johnson
JNJ
Mkt Cap360.71B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in various therapeutic areas, including those targeted by Omeros' treatments.

About

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Show more...
CEO
Dr. Gregory A. Demopulos M.D.
Employees
213
Country
United States
ISIN
US6821431029
WKN
000A0NBFF

Listings